Natalie Finn, Author at BioTuesdays

Developments

Hepion’s rencofilstat demonstrates anti-cancer activity in hepatitis C-associated cancer model

Hepion Pharmaceuticals (NASDAQ:HEPA) published a new research study in mice where rencofilstat prevented the growth of human hepatitis C virus (“HCV”)-associated liver tumors. HCV-infected mice developed small liver...

October 25, 2023

Developments

Rani posts successful drug delivery of high-capacity pill

Rani Therapeutics Holdings (NASDAQ:RANI) reported three new positive preclinical studies that support development of a high-capacity oral biologics device, known as the RaniPill HC, a version of the RaniPill capsule...

September 8, 2023

Developments

Arcutis posts positive long-term roflumilast cream results in AD

Arcutis Biotherapeutics (NASDAQ:ARQT) reported positive interim results from the INTEGUMENT-OLE long-term, open-label study of roflumilast cream 0.15% in adults and children ages six years and older with atopic...

September 7, 2023

Executive Moves

Enzo Biochem names Kara Cannon as interim CEO

Enzo Biochem (NYSE:ENZ) appointed its chief operating officer, Kara Cannon, to be interim CEO after Hamid Erfanian, former CEO, left the company, effective Sept. 5. Mr. Erfanian led the company through the sale of Enzo...

September 6, 2023

Executive Moves

Zoe Heineman joins Hygieia as VP of BD

Closely-held Hygieia, a provider of digital therapeutics for insulin management, hired Zoe Heineman as VP of business development. Ms. Heineman brings more than 30 years of expertise in strategic leadership, operations...

September 1, 2023

Developments

Sage in reorganization to support launch of ZURZUVAE, advance pipeline

Sage Therapeutics (NASDAQ:SAGE) plans to reorganize its business operations and pipeline priorities to support goals for long-term business growth, including the planned commercial launch of ZURZUVAE for women with...

August 31, 2023

Developments

Outlook Therapeutics receives CRL in wet AMD

Outlook Therapeutics (NASDAQ:OTLK) received a complete response letter (CRL) to the company’s biologics license application (BLA) for ONS-5010, an investigational ophthalmic formulation of bevacizumab under development...

August 30, 2023

Developments

ANI Pharma announces FDA approval and launch of Estradiol Gel, 0.1%

ANI Pharmaceuticals (NASDAQ:ANIP) received FDA approval for the abbreviated new drug application for Estradiol Gel, 0.1%, to treat and prevent hot flashes. ANI’s Estradiol Gel, 0.1%, is the generic version of the...

August 28, 2023

Developments

Tarsier Pharma misses endpoint in Phase 3 uveitis trial

Closely-held Tarsier Pharma of Israel did not reach the primary endpoint in the non-infectious anterior uveitis TRS4VISION trial with its TRS01 eye drops. However, a post hoc analysis of the data demonstrates the much...

August 23, 2023

Developments

LEO Pharma to acquire Timber Pharmaceuticals

LEO US Holding, a wholly-owned subsidiary of LEO Pharma A/S, entered into a definitive agreement to acquire Timber Pharmaceuticals (NYSEA:TMBR) in a total transaction value of up to $36-million. Timber is eligible to...

August 21, 2023

Author - Natalie Finn

Hepion’s rencofilstat demonstrates anti-cancer activity in hepatitis C-associated cancer model

Rani posts successful drug delivery of high-capacity pill

Arcutis posts positive long-term roflumilast cream results in AD

Enzo Biochem names Kara Cannon as interim CEO

Zoe Heineman joins Hygieia as VP of BD

Sage in reorganization to support launch of ZURZUVAE, advance pipeline

Outlook Therapeutics receives CRL in wet AMD

ANI Pharma announces FDA approval and launch of Estradiol Gel, 0.1%

Tarsier Pharma misses endpoint in Phase 3 uveitis trial

LEO Pharma to acquire Timber Pharmaceuticals

General

More